ClinicalTrials.gg
CompletedNCT01722487Updated Nov 30, 2017Results posted

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

A Phase 3 interventional study of Ibrutinib and Chlorambucil in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 108 sites in 16 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-11-30.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
10th of 83
269 · median 44
Started
2013
with 6 others
Phase 3
14 of 83
none open now
Registered
11th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by enrollment, is one of 7 that started in 2013, is one of 14 in phase 3, and was the 11th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

Read the detailed description

Study design: This is a randomized, multicenter, open-label, Phase 3 study designed to compare the safety and efficacy of Ibrutinib versus Chlorambucil in treatment-naive patients 65 years or older who have CLL or SLL.

Eligible patients will be randomized in a 1:1 ratio to Treatment Arm A or B:

  • Treatment Arm A: Oral Chlorambucil 0.5 mg/kg on Days 1 and 15 of each 28-day cycle; the dose can be increased, if well tolerated, in increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg; patients receive a minimum of 3 and a maximum of 12 cycles, in the absence of progressive disease or unacceptable toxicity.
  • Treatment Arm B: Oral Ibrutinib 420 mg/day Randomization will be stratified on Eastern Cooperative Oncology Group (ECOG) performance status (0,1 versus 2); presence of advanced Rai stage (yes/no), advanced being defined as Stages 3-4; and geographic region: US versus non-US.
03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • CLL, SLL
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females of 65 years of age or greater. Patients between the ages of 65 and 70 years of age must have 1 or more of the following comorbidities that may preclude the use of frontline chemo-immunotherapy with fludarabine, cyclophosphamide, or rituximab:

    • \< 70 mL/min using the Cockcroft-Gault equation
    • count \< 100,000/μL or \< 10 g/dL
    • clinically apparent cytopenia (autoimmune hemolytic anemia or immune thrombocytopenia)
    • performance score = 1 or 2
  2. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria (Hallek 2008)
  3. Active disease meeting at least 1 of the following IWCLL criteria (Hallek 2008) for requiring treatment:

    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia Massive, progressive, or symptomatic splenomegaly
    • Massive nodes or progressive or symptomatic lymphadenopathy
    • Progressive lymphocytosis
    • Autoimmune hemolytic anemia and/or immune thrombocytopenia that is poorly responsive to or standard therapy
    • Constitutional symptoms
  4. Measurable nodal disease by computed tomography (CT)
  5. ECOG performance status of 0-2
  6. > 4 months from randomization
  7. Adequate hematologic function, defined as (ANC) ≥ 1,000/μL (independent of growth factor support for at least 7 days prior to screening) and platelet count ≥ 50,000/μL (independent of transfusion and growth factor support for at least 7 days prior to screening)
  8. Adequate hepatic function, defined as serum (AST) and alanine transaminase (ALT) \< 2.5 x (ULN), and total ≤ 1.5 x ULN
  9. Adequate renal function, defined as estimated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation
  10. Willingness to receive all outpatient treatment, all laboratory monitoring, and all radiological evaluations at the institution that administers study drug for the entire study
  11. Willingness of male patients, if sexually active with a female of , to use an effective barrier method of during the study and for 3 months following the last dose of study drug
  12. Ability to provide written and to understand and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  1. Known involvement of the central nervous system by lymphoma or leukemia
  2. History or current evidence of Richter's transformation or prolymphocytic leukemia
  3. Documentation of deletion of the short arm of chromosome 17: del(17p13.1) in more than 20% of cells examined on any pretreatment fluorescence in situ hybridization (FISH) or cytogenetic evaluation
  4. Uncontrolled hemolytic anemia or idiopathic thrombocytopenic purpura
  5. Any previous treatment (chemotherapy, radiotherapy, and/or monoclonal antibodies) intended specifically to treat CLL/SLL
  6. Received any immunotherapy, vaccine, or drug within 4 weeks prior to randomization
  7. use within 1 week prior to first dose of study drug, with the exception of inhaled, topical, or other local administrations. Patients requiring systemic steroids at daily doses > 20 mg prednisone (or corticosteroid equivalent, see Appendix N), or those who are administered steroids for leukemia control or white blood cell (WBC)-count-lowering are excluded.
  8. Major surgery within 4 weeks prior to randomization
  9. History of prior , with the exception of the following:

    • malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician
    • adequately treated nonmelanomatous skin cancer or lentigo maligna melanoma without current evidence of disease
    • adequately treated cervical carcinoma in situ without current evidence of disease
  10. Currently active, cardiovascular disease or a history of myocardial infarction within 6 months prior to randomization
  11. Inability to swallow capsules or tablets, or disease significantly affecting gastrointestinal function
  12. Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
  13. Known history of infection with (HIV)
  14. Serologic status reflecting active or C infection
  15. History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  16. Current life-threatening illness, medical condition, or organ-system dysfunction that could compromise patient safety or put the study at risk
  17. Requirement for anticoagulation with warfarin
  18. Requirement for treatment with a strong /5 and/or CYP2D6 inhibitor
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    Ibrutinib

    Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.

    Drug: Ibrutinib

  • Active comparator
    Chlorambucil

    Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.

    Drug: Chlorambucil

Interventions

  • Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.

  • Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.

06

What researchers measure

Primary outcomes

  1. PFS (Progression Free Survival)

    The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS Progressive disease according to 2008 IWCLL guidelines was defined as: * Group A * Lymphadenopathy, increase ≥50% * Hepatomegaly, increase ≥50% * Splenomegaly, increase ≥50% * Blood lymphocytes, increase ≥ 50% over baseline * Group B * Platelets counts, decrease of ≥ 50% from baseline secondary to CLL * Hemoglobin, decrease of \> 2 g/dL from baseline secondary to CLL

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Secondary outcomes

  1. Overall Survival (OS)

    OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure.

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

  2. ORR (Overall Response Rate)

    ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

  3. Proportion of Sustained Hemoglobin Improvement

    The proportion of subjects who achieved Hemoglobin \>11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

  4. Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

    In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin \>11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

  5. Proportion of Sustained Platelet Improvement

    The proportion of subjects who achieved platelet \>100 x 10\^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

  6. Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

    In randomized subjects with baseline platelet ≤ 100 x 10\^9/L, the proportion of subjects who achieved platelet \>100 x 10\^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors.

    Time frame: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

07

Results

Posted May 4, 2016

Participant flow

Participant flow — Overall Study
MilestoneIbrutinibChlorambucil
Started136133
Completed134126
Not completed27

Outcome measures

PrimaryPFS (Progression Free Survival)

The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS Progressive disease according to 2008 IWCLL guidelines was defined as: * Group A * Lymphadenopathy, increase ≥50% * Hepatomegaly, increase ≥50% * Splenomegaly, increase ≥50% * Blood lymphocytes, increase ≥ 50% over baseline * Group B * Platelets counts, decrease of ≥ 50% from baseline secondary to CLL * Hemoglobin, decrease of \> 2 g/dL from baseline secondary to CLL

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Median · Months
PFS (Progression Free Survival)
MonthsIbrutinibChlorambucil
PFS (Progression Free Survival)NA (NA to NA)18.9 (14.1 to 22.0)
Statistical analysis
  • Chlorambucil · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.16 · 95% CI 0.09 to 0.28
SecondaryOverall Survival (OS)

OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure.

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Median · Months
Overall Survival (OS)
MonthsIbrutinibChlorambucil
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Chlorambucil · Log Rank · p = 0.0010 · Hazard ratio (hr): 0.16 · 95% CI 0.05 to 0.56
SecondaryORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Number · percentage of participants
ORR (Overall Response Rate)
percentage of participantsIbrutinibChlorambucil
ORR (Overall Response Rate)82.435.3
Statistical analysis
  • Chlorambucil · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryProportion of Sustained Hemoglobin Improvement

The proportion of subjects who achieved Hemoglobin \>11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Number · Percentage of Participants
Proportion of Sustained Hemoglobin Improvement
Percentage of ParticipantsIbrutinibChlorambucil
Proportion of Sustained Hemoglobin Improvement45.620.3
Statistical analysis
  • Chlorambucil · Chi-squared · p = <0.0001
SecondaryProportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin \>11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Number · Percentage of Participants
Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia
Percentage of ParticipantsIbrutinibChlorambucil
Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia84.345.5
Statistical analysis
  • Chlorambucil · Chi-squared · p = <0.0001
SecondaryProportion of Sustained Platelet Improvement

The proportion of subjects who achieved platelet \>100 x 10\^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Number · Percentage of Participants
Proportion of Sustained Platelet Improvement
Percentage of ParticipantsIbrutinibChlorambucil
Proportion of Sustained Platelet Improvement27.211.3
Statistical analysis
  • Chlorambucil · Chi-squared · p = .0009
SecondaryProportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

In randomized subjects with baseline platelet ≤ 100 x 10\^9/L, the proportion of subjects who achieved platelet \>100 x 10\^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors.

Time frame:
Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.
Reported as:
Number · Percentage of Participants
Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia
Percentage of ParticipantsIbrutinibChlorambucil
Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia77.142.9
Statistical analysis
  • Chlorambucil · Chi-squared · p = .0054

Adverse events

Collected over From first dose of study drug to within 30 days of last dose or starting new anti-cancer therapy, whichever occurs earlier, up to 04May2015 ( data cutoff date for final analysis).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCI-32765—55/135 (40.7%)133/135 (98.5%)
Chlorambucil—33/132 (25%)123/132 (93.2%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventPCI-32765Chlorambucil
PyrexiaGeneral disorders1/1355/132
PneumoniaInfections and infestations5/1352/132
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1350/132
HyponatraemiaMetabolism and nutrition disorders3/1350/132
AnaemiaBlood and lymphatic system disorders2/1352/132
Febrile neutropeniaBlood and lymphatic system disorders2/1352/132
NeutropeniaBlood and lymphatic system disorders1/1352/132
SyncopeNervous system disorders0/1352/132
Pleural effusionRespiratory, thoracic and mediastinal disorders2/1352/132
Atrial fibrillationCardiac disorders2/1351/132
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPCI-32765Chlorambucil
DiarrhoeaGastrointestinal disorders57/13522/132
NauseaGastrointestinal disorders30/13552/132
FatigueGeneral disorders41/13550/132
CoughRespiratory, thoracic and mediastinal disorders30/13520/132
NeutropeniaBlood and lymphatic system disorders20/13529/132
AnaemiaBlood and lymphatic system disorders24/13527/132
VomitingGastrointestinal disorders18/13527/132
Oedema peripheralGeneral disorders25/13512/132
Upper respiratory tract infectionInfections and infestations22/13523/132
Dry eyeEye disorders23/1356/132

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IbrutinibChlorambucilTotal
<=18 years000
Between 18 and 65 years000
>=65 years136133269
Age, Continuous
Age, Continuous(years)IbrutinibChlorambucilTotal
Mean73.1 ± 5.6773.4 ± 5.9573.3 ± 5.81
Sex: Female, Male
Sex: Female, Male(Participants)IbrutinibChlorambucilTotal
Female4852100
Male8881169
08

Study locations

108 sites
  • Site Reference ID/Investigator #047
    Duarte, California 91010, United States
  • Site Reference ID/Investigator #408
    La Jolla, California 92093, United States
  • Site Reference ID/Investigator #720
    Santa Rosa, California 95403, United States
  • Site Reference ID/Investigator #038
    Stanford, California 94305, United States
  • Site Reference ID/Investigator #125
    Atlanta, Georgia 30318, United States
  • Site Reference ID/Investigator #126
    Chicago, Illinois 60637, United States
  • Site Reference ID/Investigator #071
    Louisville, Kentucky 40207, United States
  • Site Reference ID/Investigator #307
    Worcester, Massachusetts 01655, United States
  • Site Reference ID/Investigator #387
    Ann Arbor, Michigan 48109, United States
  • Site Reference ID/Investigator #221
    Saint Louis, Missouri 63110, United States
  • Site Reference ID/Investigator #712
    Las Vegas, Nevada 89169, United States
  • Site Reference ID/Investigator #350
    New Hyde Park, New York 11042, United States
  • Site Reference ID/Investigator #127
    Rochester, New York 14642, United States
  • Site Reference ID/Investigator #656
    Goldsboro, North Carolina 27534, United States
  • Site Reference ID/Investigator #734
    Columbus, Ohio 43219, United States
  • Site Reference ID/Investigator #677
    Portland, Oregon 97227, United States
  • Site Reference ID/Investigator #050
    Pittsburgh, Pennsylvania 15232, United States
  • Site Reference ID/Investigator #032
    Houston, Texas 77030, United States
  • Site Reference ID/Investigator #381
    Laredo, Texas 78041, United States
  • Site Reference ID/Investigator #653
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator #404
    Seattle, Washington 98109, United States
  • Site Reference ID/Investigator #731
    Walla Walla, Washington 99362, United States
  • Site Reference ID/Investigator #654
    Kogarah, New South Wales 2217, Australia
  • Site Reference ID/Investigator #503
    Woolloongabba, Queensland 4102, Australia
  • Site Reference ID/Investigator #163
    Bedford Park, South Australia 5042, Australia
  • Site Reference ID/Investigator #555
    Hobart, Tasmania 7000, Australia
  • Site Reference ID/Investigator #193
    Box Hill, Victoria 3128, Australia
  • Site Reference ID/Investigator #556
    Clayton, Victoria 3168, Australia
  • Site Reference ID/Investigator #501
    Fitzroy, Victoria 3065, Australia
  • Site Reference ID/Investigator #715
    Frankston, Victoria 3199, Australia
  • Site Reference ID/Investigator #558
    Geelong, Victoria 3220, Australia
  • Site Reference ID/Investigator #170
    Heidelberg, Victoria 3084, Australia
  • Site Reference ID/Investigator #164
    Bruxelles, Brussells 1200, Belgium
  • Site Reference ID/Investigator #727
    Yvoir, Namur 5530, Belgium
  • Site Reference ID/Investigator #560
    Gent, Oost-Vlaanderen 9000, Belgium
  • Site Reference ID/Investigator #559
    Leuven, Vlaams Brabant 3000, Belgium
  • Site Reference ID/Investigator #628
    Brugge, West-Vlaanderen 8000, Belgium
  • Site Reference ID/Investigator #561
    Antwerpen, 2060, Belgium
  • Site Reference ID/Investigator #184
    Brussells, 1000, Belgium
  • Site Reference ID/Investigator #157
    Calgary, Alberta T2N 4N2, Canada
  • Site Reference ID/Investigator #018
    Edmonton, Alberta T6G 1Z2, Canada
  • Site Reference ID/Investigator #159
    Ottawa, Ontario K1H 8L6, Canada
  • Site Reference ID/Investigator #674
    Guangzhou, Guangdong 510060, China
  • Site Reference ID/Investigator #671
    Nanjing, Jiangsu 210029, China
  • Site Reference ID/Investigator #675
    Hangzhou, Zhejiang 31003, China
  • Site Reference ID/Investigator #670
    Beijing, 100142, China
  • Site Reference ID/Investigator #673
    Beijing, 100191, China
  • Site Reference ID/Investigator #564
    Hradec Kralove, Kralovehradecky Kraj 500 05, Czechia
  • Site Reference ID/Investigator #562
    Brno, 625 00, Czechia
  • Site Reference ID/Investigator #566
    Plzen-Lochotin, 304 60, Czechia
  • Site Reference ID/Investigator #572
    Dublin, 7, Ireland
  • Site Reference ID/Investigator #570
    Dublin, 8, Ireland
  • Site Reference ID/Investigator #571
    Galway, ST4 6QG, Ireland
  • Site Reference ID/Investigator #573
    Haifa, 31048, Israel
  • Site Reference ID/Investigator #576
    Haifa, 31096, Israel
  • Site Reference ID/Investigator #577
    Jerusalem, 91031, Israel
  • Site Reference ID/Investigator #578
    Nahariya, 22100, Israel
  • Site Reference ID/Investigator #575
    Petaẖ Tiqwa, 49100, Israel
  • Site Reference ID/Investigator #574
    Ramat Gan, 52621, Israel
  • Site Reference ID/Investigator #583
    Roma, Lazio 00161, Italy
  • Site Reference ID/Investigator #522
    Rozzano, Milano 20089, Italy
  • Site Reference ID/Investigator #582
    Novara, Piemonte 28100, Italy
  • Site Reference ID/Investigator #527
    Padova, Veneto 35128, Italy
  • Site Reference ID/Investigator #580
    Bologna, 40138, Italy
  • Site Reference ID/Investigator #584
    Milano, 20122, Italy
  • Site Reference ID/Investigator #523
    Milano, 20132, Italy
  • Site Reference ID/Investigator #581
    Milano, 20162, Italy
  • Site Reference ID/Investigator #524
    Modena, 41100, Italy
  • Site Reference ID/Investigator #589
    Christchurch, Canterbury 8011, New Zealand
  • Site Reference ID/Investigator #586
    Hamilton, Waikato 3240, New Zealand
  • Site Reference ID/Investigator #663
    Auckland, 0622, New Zealand
  • Site Reference ID/Investigator #588
    Auckland, 1023, New Zealand
  • Site Reference ID/Investigator #587
    Wellington, 6021, New Zealand
  • Site Reference ID/Investigator #590
    Lublin, Lubelskie 20-081, Poland
  • Site Reference ID/Investigator #592
    Brzozowie, Podkarpackie 36.200, Poland
  • Site Reference ID/Investigator #591
    Chorzow, 40, Poland
  • Site Reference ID/Investigator #529
    Gdansk, 80-952, Poland
  • Site Reference ID/Investigator #531
    Lodz, 93-510, Poland
  • Site Reference ID/Investigator #707
    Ryazan, 390039, Russian Federation
  • Site Reference ID/Investigator #304
    Yaroslavl, 150062, Russian Federation
  • Site Reference ID/Investigator #536
    Majadahonda, Madrid 28222, Spain
  • Site Reference ID/Investigator #534
    Barcelona, 08035, Spain
  • Site Reference ID/Investigator #533
    Barcelona, 08036, Spain
  • Site Reference ID/Investigator #535
    Barcelona, 08041, Spain
  • Site Reference ID/Investigator #604
    Barcelona, 08908, Spain
  • Site Reference ID/Investigator #537
    Madrid, 28050, Spain
  • Site Reference ID/Investigator #608
    Ankara, 06500, Turkey
  • Site Reference ID/Investigator #606
    Ankara, 06590, Turkey
  • Site Reference ID/Investigator #599
    Istanbul, 34390, Turkey
  • Site Reference ID/Investigator #714
    Izmir, 35040, Turkey
  • Site Reference ID/Investigator #601
    Izmir, 35340, Turkey
  • Site Reference ID/Investigator #602
    Kayseri, 38039, Turkey
  • Site Reference ID/Investigator #597
    Cherkasy, Cherkas'ka Oblast 18009, Ukraine
  • Site Reference ID/Investigator #594
    Dnipropetrovsk, Dnipropetrovs'ka Oblast' 49102, Ukraine
  • Site Reference ID/Investigator #725
    Kharkiv, Kharkivs'ka Oblast 61070, Ukraine
  • Site Reference ID/Investigator #596
    Lviv, L'vivs'ka Oblast 79044, Ukraine
  • Site Reference ID/Investigator #598
    Simferopol, Respublika Krym 95023, Ukraine
  • Site Reference ID/Investigator #595
    Vinnytsia, Vinnyts'ka Oblast 21018, Ukraine
  • Site Reference ID/Investigator #724
    Zhytomyr, Zhytomyrs'ka Oblast' 10022, Ukraine
  • Site Reference ID/Investigator #551
    Bournemouth, Dorset BH7 7DW, United Kingdom

Showing the first 100 of 108 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434. PubMed 35377947 ↗
  • Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 Jun;63(6):1375-1386. doi: 10.1080/10428194.2021.2020779. Epub 2022 Jan 11. PubMed 35014928 ↗
  • Allan JN, Shanafelt T, Wiestner A, Moreno C, O'Brien SM, Li J, Krigsfeld G, Dean JP, Ahn IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022 Feb;196(4):947-953. doi: 10.1111/bjh.17984. Epub 2021 Dec 5. PubMed 34865212 ↗
  • Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. PubMed 31196847 ↗
  • Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7. PubMed 29880603 ↗
  • Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. PubMed 28751558 ↗
  • Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6. PubMed 26639149 ↗

Individual participant data

Plan to share: No — We share this information with FDA and other authorities for the purposes of analyzing the study but not with other researchers

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2012
First posted
Nov 6, 2012
Start
Mar 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
May 4, 2016
Last update
Nov 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01722487
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 6, 2012
Start date
Mar 2013
Primary completion
May 2015
Completion
May 2015
Results posted
May 4, 2016
Last update
Nov 30, 2017

Study contacts

Lori Styles, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion